Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Summary
As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.
Key Details
Gender
All
Age Range
45 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2021-08-01
Completion Date
2025-12-31
Last Updated
2025-04-09
Healthy Volunteers
Yes
Conditions
Interventions
Denosumab
Desumumab, 60mg single injection
Locations (1)
Wuhan Union Hospital
Wuhan, Hubei, China